Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC1416 in moderate to severe asthma
NCT06911866Phase 1Completed
- Sponsor
- Nanjing RegeneCore Biotech Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing RC1416 with Placebo (2 arms). Primary endpoints: Adverse Events up to 141 days, Serious Adverse Events up to 141 days and 4 more. Started Oct 2024; status: completed.
02
Drugs
RC1416
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06911866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911866.